Gene therapy · Gene replacement · developed by Krystal Biotech
KB407 is a replication-defective herpes simplex virus type 1 vector that carries the full-length human CFTR gene and is given as a nebulized solution. It is being studied in cystic fibrosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05504837 | Phase 1 | Cystic Fibrosis | Recruiting | KRYS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cystic Fibrosis
Updated Oct 18, 2026. Something wrong or missing? Report it on the KRYS page.
See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KRYS catalysts and pipeline →